Merck & Co., Inc. (NYSE:MRK) EVP Jennifer Zachary Sells 80,315 Shares of Stock

Merck & Co., Inc. (NYSE:MRK) EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Merck & Co., Inc. Trading Up 2.0%

Shares of MRK stock traded up $2.65 on Thursday, reaching $135.57. 8,875,510 shares of the stock were exchanged, compared to its average volume of 10,698,729. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.68. The stock has a market cap of $334.49 billion, a PE ratio of 108.46, a P/E/G ratio of 5.62 and a beta of 0.19. The stock has a 50 day moving average price of $124.94 and a 200 day moving average price of $119.64.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the business earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Hedge Funds Weigh In On Merck & Co., Inc.

Several institutional investors have recently modified their holdings of MRK. Brighton Jones LLC grew its holdings in shares of Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after buying an additional 8,710 shares during the period. Sivia Capital Partners LLC raised its stake in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after buying an additional 3,941 shares during the period. Diversify Advisory Services LLC lifted its holdings in Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after acquiring an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC lifted its holdings in Merck & Co., Inc. by 22.2% during the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after acquiring an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after acquiring an additional 359,356 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades support the shares: Daiwa Securities raised Merck to “outperform” with a $143 price target, while Argus maintained a “buy” rating and lifted its target to $145. These actions reinforce the view that Merck’s recent momentum can continue. Merck analyst price target article
• Positive Sentiment: Keytruda and the core business remain strong: Merck’s second-quarter growth was driven primarily by Keytruda demand in early-stage and metastatic cancers, oncology products, new launches and Animal Health. Quarterly revenue of $16.61 billion exceeded the $16.37 billion consensus estimate, and revenue increased 5.1% year over year. Merck second-quarter earnings call article
• Positive Sentiment: Pipeline diversification is advancing: The FDA and European Medicines Agency accepted applications for broader ENFLONSIA use to prevent RSV in vulnerable young children. Expanded approval could create an additional growth avenue beyond oncology as Keytruda approaches eventual patent expiration. Merck ENFLONSIA RSV regulatory review article
• Neutral Sentiment: Earnings expectations are stable to slightly improved: Erste Group raised its FY2026 EPS estimate to $2.75 from $2.70, close to the roughly $2.77 consensus. Merck also declared its regular $0.85 quarterly dividend, or $3.40 annualized.
• Negative Sentiment: Keytruda concentration remains the main risk: Analysts caution that patent loss and increasing competition could eventually slow the drug’s sales growth, making the company’s pipeline and newer products increasingly important. Keytruda growth outlook article
• Negative Sentiment: Recent insider selling may temper sentiment: EVP Richard Deluca disclosed sales totaling more than 45,000 shares across transactions from August 10–12, while retaining a substantial position. The sales are not necessarily a fundamental signal, but could modestly weigh on investor confidence.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. CICC Research started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target for the company. Guggenheim raised their price objective on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Bank of America lifted their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Citigroup started coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Fifteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus target price of $135.50.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.